Unknown NA INTERVENTIONAL 2-arm NCT03920605

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis (HBV)

Study on Optimized Treatment of Peginterferon Alfa 2a or 2b in Anti-virus Treatment Experienced Patients With Hepatitis b Virus Related Liver Fibrosis

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

Conditions Hepatitis B Liver Fibrosis

Interventions Peginterferon Alfa-2a Peginterferon Alfa-2b Tenofovir Disoproxil Fumarate

Updated 6 times since 2019 Last updated: May 20, 2019 Started: Feb 1, 2019 Primary completion: Oct 30, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hepatitis B and Liver Fibrosis, this trial is ongoing. The trial is conducted by Third Affiliated Hospital, Sun Yat-Sen University and has accumulated 6 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting NA
Jun 2019 — Jan 2021 [monthly]

Recruiting NA

▶ Show 1 earlier version

May 2019 — Jun 2019 [monthly]

Recruiting NA

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Third Affiliated Hospital, Sun Yat-Sen University

Data source: Third Affiliated Hospital, Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China